Hello NMPA: New English Website For China's Regulator, Inspection Scheme Bolstered
China's main drug regulatory agency is hoping to tell its story to the world via a new English website, while the vaccines and other sectors are poised to see increasing quality inspections as the country builds up a new two-level scheme. Provincial reimbursement lists are also being halted.
You may also be interested in...
China grants approvals to Gilead’s HIV combo Biktarvy and Mitsubishi Tanabe Pharma’s Radicava in the latest batch of new product clearances. Meanwhile, a new online database for marketing authorization holders goes live.
China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.